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Understanding the new FDA pregnancy and lactation labeling rules☆Dermatologists should be aware that the new Pregnancy and Lac-
tation Labeling Rule (PLLR) has taken effect on June 30th, 2015. This
mandate from the Federal Drug Administration (FDA) eliminated
the standard pregnancy category letters for prescription medications
(A, B, C, D and X). The new recommendations are now in the form of
drug labeling that contains increased detail but also increased com-
plexity. This editorial describes the newdrug-labeling rule and its po-
tential impact in clinical dermatology.
The PLLR introduced a new drug labeling schema to help physi-
cians better communicate the risks and beneﬁts of pharmacologic
treatment to patients during pregnancy and lactation. Sandra
Kweder, M.D., Deputy Director of the Ofﬁce of New Drugs in the
FDA’s Center for Drug Evaluation and Research, stated, “The previous
letter category system was overly simplistic and was misinterpreted
as a grading system, which gave an over-simpliﬁed view of the prod-
uct risk.” (US Food andDrugAdministration, 2015) Consequently, the
new package insert content and formatting requirements aim to pro-
vide a more consistent way of disclosing relevant information about
the risks and beneﬁts of prescription drugs and biological products
used during pregnancy and breastfeeding. However, some have
expressed criticism of the PLLR. Many question how labels will be re-
vised to reﬂect new data as it becomes available. Drugmanufacturers
face a signiﬁcant challenge in condensing vast amounts of varying
quality data into concise, clear paragraphs.
Despite these challenges, the rule immediately applies to all drugs
approved by the FDA after June 30th 2015 and requires that all labels
be continually updated as new information becomes available (US
Food and Drug Administration, 2015). Pregnancy labels for products
approved between 2001 and June 30th 2015 will be revised using a
staggered implementation schedule, and those approved before
2001 must be revised within 3 years (US Food and Drug Administra-
tion, 2015). To aid in transition, the FDA issued draft guidance to as-
sist drug manufacturers in complying with the new labeling
content and format requirements (US Food and Drug Administration,
2015). Unfortunately, labels for over-the-countermedications are not
affected by the PLLR.
The most notable change of the PLLR is that it will remove arbi-
trary and often misinterpreted pregnancy-labeling categories for
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that includes the “risks of using a drug during pregnancy and lacta-
tion, a discussion of the data supporting that summary, and relevant
information to help health care providersmake prescribing decisions
and counselwomen about the use of drugs duringpregnancy and lac-
tation.” (Food and Drug Administration, HHS, 2014).
This improved labeling schema is timely since nine out of ten
women take at least one medication during pregnancy, and the use
of four or more medications during pregnancy has doubled over the
last 30 years (Mosley et al., 2015). Many pregnant women also suffer
from chronic conditions such as asthma, high blood pressure, diabe-
tes, mental illness, rheumatologic, and dermatologic disease that ne-
cessitate continued medical therapy during pregnancy and lactation.
The PLLR requires the use of three new subsections titled “Preg-
nancy,” “Lactation” and “Females and Males of Reproductive Poten-
tial.” This replaces the old schema (Fig. 1) that contained 3 distinct
subsections that described “Pregnancy,” “Labor and Delivery,” and
“Nursing Mothers.” “Pregnancy” and “Labor and Delivery” have now
been combined into “Pregnancy,” and the old subsection of “Nursing
Mothers” is now labeled “Lactation.” In addition, a new subsection
has been created to describe risks to “Females and Males of Repro-
ductive Potential.”
The “Pregnancy” subsection requires a previously recommended
pregnancy exposure registry for drugs approved for use during preg-
nancy. It also contains a summary of the available data on any partic-
ular developmental outcome speciﬁc to gestational timing of
exposure, which was previously not reported. The “Lactation” sub-
section provides additional information regarding the amount of
drug transferred to breast milk and the speciﬁc potential effects on
breastfed infants. Finally, the “Females andMales of Reproductive Po-
tential” subsection discusses the need for pregnancy testing, contra-
ception recommendations, and includes information about drug
related infertility.
The PLLR has several promising implications for clinical practice.
In place of an arbitrary lettering system, detailed risk summaries
providemore comprehensive information derived from clinical expe-
rience (if any), animal data, and concerns related to the pharmaco-
logic activity of the drug (Addis et al., 2000; Boothby and Doering,
2001; Doering et al., 2002). This information puts the potential effects
of the drug into perspective to provide a more individualized risk-
beneﬁt analysis by patients and physicians. The new labeling system
will also reduce the “innocent until proven guilty” bias, where untest-
ed drugs with no known harmful side effects were perceived to be
safer (Category B) than tested drugswith known side effects (Catego-
ry C) (Danesh and Murase, 2015).matologic Society. This is an open access article under the CC BY-NC-ND license
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Fig. 1. Comparison of the current prescription drug labeling with the new PLLR labeling requirements.
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on biologic drugs is derived from spontaneous reports or underpow-
ered cohort studies, which contain inconsistent information that
requires scrutiny when assessing outcomes (Calligaro et al., 2015).
Postmarketing surveillance efforts have not been a priority formanu-
facturers in most cases, but the PLLR now requires pregnancy regis-
tries to become a routine part of postmarketing surveillance. This
should provide adequate data to help physicians, pregnant patients,
and breastfeeding mothers make complex healthcare decisions.
The PLLR also poses a number of challenges. The new system is
more explicit about the sources of data on the label, and it is likelyFig. 2. Sample step-by-step instructions for how to view the pto further expose that most pharmaceutical data relating to pregnan-
cy is based on animal studies (92.9% from animal studies verse 5.2%
from human pregnancy studies) (Mazer-Amirshahi et al., 2014;
Chambers, 2014). The same can be said for breast-feeding labels.
Data was not available on 47.9% of all labels; data for animals was
only available on 42.7% of labels, and data for humans was only pres-
ent on 4.7% of labels (Mazer-Amirshahi et al., 2014). The rule pro-
vides practitioners with more detailed information regarding
pregnancy, lactation, and reproduction. It, therefore, places an in-
creased responsibility on dermatologists to ensure that the paucity
of available safety data is explained to their patients.regnancy, lactation, and male fertility data for sonidegib.
7EditorialPatients often desire more information than is currently provided
(Edwards et al., 2002). Previously, physicians were able to use preg-
nancy categories as simple surrogates for risk stratiﬁcation, with A
being considered the safest and X the most dangerous (US Food and
Drug Administration website, 1999). The new labels require physi-
cians to not only read and understand the potential risks of amedica-
tion but also interpret literature that supports these risks. Physicians
must then explain these risks in a clear concise manner to patients
before a decision is made about starting a medication. The challenge
of explaining probabilities to patients regarding risk is well known,
and there is no universally accepted format for doing so (Danesh
and Murase, 2015; Visschers et al., 2009). These obstacles will likely
push physicians to develop new ways of coherently and efﬁciently
engaging patients in making difﬁcult decisions. To make the transi-
tion easier, “decision aids” that include visual presentations of risk in-
formation may be used to relate information to more familiar risks
(Edwards et al., 2002). For example, some patientsmay prefer simple
bar charts as opposed to a verbal explanation that explains risk
verse beneﬁts.
Despite these challenges, the PLLR presents an opportunity to im-
prove patient care. It is well known that good communication is a
requisite to good patient care and enhances the patient-physician re-
lationship (Singh, 2015). The PLLRwillmotivate physicians to further
develop their communication skills and better equip them to help pa-
tients make informed healthcare decisions. A helpful text for physi-
cians with questions in this area is is "Drugs in Pregnancy and
Lactation" by Gerald G. Briggs (Briggs et al., 2012). All dermatologists
and other physicians should familiarize themselves with the ﬁnal
PLLR guidelines available at http://federalregister.gov/a/2014-
28241, and drug labels may be found at http://dailymed.nlm.nih.
gov/dailymed/index.cfm (Fig. 2).
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